Pivotal Therapeutics Inc. Generates Positive Feedback at European Society of Cardiology Congress 2012

Pivotal Therapeutics Inc. Generates Positive Feedback at European Society of Cardiology Congress 2012 PR Newswire WOODBRIDGE, Ontario, September 4, 2012 WOODBRIDGE, Ontario, September 4, 2012 /PRNewswire/ -- Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular disease and overall health, is pleased to announce that the company received a positive response to its lead product VASCAZEN™ at the European Society of Cardiology (ESC) Congress 2012 in Munich, Germany last week. The ESC Congress provided the Company a platform to inform healthcare professionals from around the world on the benefits of VASCAZEN™ and its unique approach to Omega-3 therapy. The expanded scientific study presented at the ESC Congress that demonstrated the superiority of VASCAZEN™'s formulation was well received by the large audience of delegates interested in Omega-3 and cardiovascular health. The study, entitled The highly purified EPA:DHA 6:1 product evokes potent endothelium-dependent relaxations of porcine coronary artery rings via the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of eNOS, was authored by F. Zgheel, M. Alhosin, C. Auger and V.B. Schini-Kerth and conducted at the University of Strasbourg, Illkirch, France.